2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2020
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic Oncology 2020, 157: 161-166. PMID: 31924334, PMCID: PMC7127981, DOI: 10.1016/j.ygyno.2019.12.034.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsRecurrent cervical cancerPD-L1 expressionPlatinum-based chemotherapyCervical cancerStable diseaseGrade 3 treatment-related adverse eventsGrade 4 treatment-related adverse eventsGrade 5 treatment-related adverse eventsECOG PS 0Prior systemic therapyRecurrent cervical carcinomaResponse/toxicitySingle-agent nivolumabSystemic chemotherapy regimenTolerability of nivolumabImmune checkpoint inhibitorsPercent of patientsAcceptable safety profilePhase II trialKey eligibility criteriaPhase II evaluationECOG PSNivolumab 3RECIST 1.1
2019
Ovarian Teratomas in Women With Anti-N-methyl-D-Aspartate Receptor Encephalitis
Nolan A, Buza N, Margeta M, Rabban JT. Ovarian Teratomas in Women With Anti-N-methyl-D-Aspartate Receptor Encephalitis. The American Journal Of Surgical Pathology 2019, 43: 949-964. PMID: 31021857, DOI: 10.1097/pas.0000000000001249.Peer-Reviewed Original ResearchConceptsNeuroglial tissueLymphoid aggregatesControl teratomasGross pathologic featuresGerminal centersReceptor encephalitisPathologic featuresOvarian teratomaAnti-N-Methyl-D-Aspartate Receptor EncephalitisD-aspartate receptor encephalitisDiffuse inflammatory infiltrateImmune cell populationsMature cystic teratomaGeneration of autoantibodiesCell populationsCentral nervous systemGanglion cell clustersAssociated teratomaIncidental oophorectomyOvarian specimenAsymptomatic womenAutoimmune syndromeInflammatory infiltrateCystic teratomaAstrocyte population
2014
Genotyping Diagnosis of Nongestational Choriocarcinoma Involving Fallopian Tube and Broad Ligament
Buza N, Rutherford T, Hui P. Genotyping Diagnosis of Nongestational Choriocarcinoma Involving Fallopian Tube and Broad Ligament. International Journal Of Gynecological Pathology 2014, 33: 58-63. PMID: 24300537, DOI: 10.1097/pgp.0b013e31827cd386.Peer-Reviewed Original ResearchConceptsBroad ligamentFallopian tubePelvic lymph node metastasisMultiagent chemotherapy regimenRecurrence 26 monthsRight adnexal massRight fallopian tubeLymph node metastasisOnly necrotic tissueLast menstrual periodLarge tumor massMicroscopic examinationChemotherapy regimenEctopic pregnancyMultiagent chemotherapyNongestational choriocarcinomaPure choriocarcinomaNode metastasisPatient ageInitial diagnosisInitial presentationGestational choriocarcinomaAdnexal massesFinal diagnosisEmergency room